Floatz logo

Prevnar 13

Pneumococcal Infections

Merck Sharp & Dohme LLCvaccinePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Pneumococcal Infections cohort.

Asset / SponsorPhaseRating
Conjugated Pneumococcal Vaccine
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 4BBB
Prevenar 13
Poitiers University Hospital
Phase 4BBB
Ppsv23
Poitiers University Hospital
Phase 4BB
Prevnar 20
Poitiers University Hospital
Phase 4BB
Ppsv23
Poitiers University Hospital
Phase 4BB

View all 10 →

Same molecule, other indications

Prevnar 13 is also rated in:

acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
56 / 100
View asset →
lymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →